Nanoparticles decorated with a small cyclic FcRn-binding peptide crossed the intestinal barrier, avoided protein corona formation, and successfully delivered the peptide drug exenatide orally in diabetic mice — producing significant blood sugar reduction.
Significant hypoglycemic responseoral exenatide delivered via FcRn-binding peptide nanoparticles in diabetic mice — with superior gut transport and reduced protein corona vs. antibody-coated particles
What the researchers found
Small cyclic FcRn-binding peptide-decorated nanoparticles showed superior intestinal transport, reduced protein corona formation, and effective oral delivery of exenatide in diabetic mice compared to larger IgG-decorated nanoparticles.
Why it matters
Oral delivery of peptide drugs would eliminate the need for daily injections — a major barrier to patient compliance for diabetes and other chronic diseases. This study demonstrates that the right surface coating (a small peptide vs. a large protein) can make or break oral nanoparticle delivery by controlling protein corona formation.
The numbers in context
Mesoporous silica nanoparticles (MSNs) with ligand modifications; demonstrated GI survival and liver targeting with reduced protein corona.
How the study worked
Functionalized mesoporous silica nanoparticles with either a small cyclic FcRn-binding peptide (MSNs-FcBP) or large IgG Fc fragments (MSNs-Fc). Compared mucus diffusion, intestinal transport, protein corona formation, and liver accumulation. Conducted pharmacokinetic and pharmacodynamic studies in diabetic mice with oral exenatide delivery.
Who was studied
Preclinical oral drug delivery study
What this study cannot tell us
Mouse study — human GI tract physiology differs significantly. Long-term safety of silica nanoparticle accumulation in the liver needs assessment. The exenatide dose delivered orally may not match injectable bioavailability. Scale-up of peptide-functionalized nanoparticles for manufacturing is complex.
How to read the evidence
Preliminary — animal study demonstrating proof-of-concept for oral peptide delivery in a diabetic mouse model. Compelling pharmacokinetic and pharmacodynamic data, but human translation is unproven.
When this study was published
Published in 2024, addressing the cutting-edge challenge of oral peptide drug delivery using nanoparticle technology.
The bigger picture
This work addresses one of pharmaceutical science's biggest challenges: making peptide drugs orally available. The key insight — that smaller targeting ligands outperform larger ones by reducing protein corona formation — is broadly applicable beyond exenatide. It could transform delivery of GLP-1 agonists, insulin, and other peptide therapeutics that currently require injection.
Questions still open
- What percentage of the oral exenatide dose actually reaches systemic circulation compared to injection?
- Is the silica nanoparticle carrier safe for repeated daily dosing over months to years?
- Can this FcRn-binding peptide approach work for larger peptide drugs like insulin or semaglutide?
Common questions
Why can't you just swallow a pill of exenatide?
Why does the size of the surface coating matter so much?
Read the original research
Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.
ACS nano, 18(52), 35310-35324
Citation
Wang, Jie; Zhang, Zilong; Zhang, Zhuan; Zou, Zhiwen; Zhuo, Yan; Liu, Chang; Nie, Di; Gan, Yong; Yu, Miaorong. (2024). Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.. ACS nano, 18(52), 35310-35324. https://doi.org/10.1021/acsnano.4c11453